Research programme: DDR targeting therapeutics - Acrivon Therapeutics
Latest Information Update: 15 Sep 2021
At a glance
- Originator Acrivon Therapeutics
- Class Antineoplastics
- Mechanism of Action DNA damage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 31 Aug 2021 Early research in Cancer in USA (unspecified route) (Acrivon Therapeutics pipeline, August 2021)